There is a newer version of the record available.

Published October 2020 | Version v1
Journal article

Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells

  • 1. Sechenov First Moscow State Medical University. Institute of Molecular Medicine (Russian Federation)
  • 2. University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison. Department of Medicine (United States)
  • 3. University of Russia (RUDN University). Peoples' Friendship (Russian Federation)
  • 4. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University (Russian Federation)

Description

Purpose

: Transformed cells are vulnerable to depletion of certain amino acids. Lysine oxidase (LO) catalyzes the oxidative deamination of lysine, resulting in lysine depletion and hydrogen peroxide production. Although LO has broad antitumor activity in preclinical models, the cytotoxic mechanisms of LO are poorly understood.

Methods

: Triple (ER/PR/HER2)-negative breast cancer (TNBC) cells were treated with control media, lysine-free media or control media supplemented with LO and examined for cell viability, caspase activation, induction of reactive oxygen species (ROS) and antioxidant signaling. To determine the role of nuclear factor erythroid 2-related factor 2 (NRF2) and thioredoxin reductase-1 (TXNRD1) in LO-induced cell death, NRF2 and TXNRD1 were individually silenced by RNAi. Additionally, the pan-TXNRD inhibitor auranofin was used in combination with LO.

Results

: LO activates caspase-independent cell death that is suppressed by necroptosis and ferroptosis inhibitors, which are inactive against lysine depletion, pointing to fundamental differences between LO and lysine depletion. LO rapidly induces ROS with a return to baseline levels within 24 h that coincides temporally with induction of TXNRD activity, the rate-limiting enzyme in the thioredoxin antioxidant pathway. ROS induction is required for LO-mediated cell death and NRF2-dependent induction of TXNRD1. Silencing NRF2 or TXNRD1 enhances the cytotoxicity of LO. The pan-TXNRD inhibitor auranofin is synergistic with LO against transformed breast epithelial cells, but not untransformed cells, underscoring the tumor-selectivity of this strategy.

Conclusions

: LO exposes a redox vulnerability of TNBC cells to TXNRD inhibition by rendering tumor cells dependent on the thioredoxin antioxidant pathway for survival.

Additional details

Identifiers

Publishing Information

Journal Title
Breast Cancer Research and Treatment
Journal Volume
183
Journal Issue
3
Journal Page Range
p. 549-564
ISSN
0167-6806
CODEN
BCTRD6

Optional Information

Copyright
Copyright (c) 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020